BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:COVID-19 has hit the pharmaceutical industry in the mergers an
 d acquisitions\, IP\, and due diligence areas within the life science ind
 ustry. The challenges arise as pharma companies cannot successfully perfo
 rm their due diligence or close deals virtually\, which creates a barrier
  to deals while there is an increase in the sellers market. However\, pro
 fessionals say that COVID-19 and the production of vaccines grabbed new e
 yes to the life science space - which is likely to increase investor inte
 rest and awareness to the role it plays around the world. Even so\, they 
 believe that drug pricing conversations may begin again due to the new he
 althcare policies of the presidential administration where the US will ma
 inly focus on biopharma investors.\n\nWithin new trends emerging the pres
 sure to meet growth expectations are placing added emphasis and challenge
 s with internal pipeline and development challenges are now focused on M&
 amp\;A activities for Life Science Companies. It is imperative for today’
 s organizations to develop robust M&amp\;A capabilities that address the 
 challenges and opportunities of diversification\; joint ventures\, allian
 ces\, and licensing deals\, and emerging markets.\n\nTop Reasons to Atten
 d:- Maximize marketing efforts in order to increase facilities and IP due
  diligence.- Evaluating new insights on reimbursements\, rules and regula
 tions and how it impacts deal-making while mitigating risks.- Understandi
 ng the role and future of evolving trends such as digital therapeutics an
 d gene therapy.- Refine your growth strategies by implementing M&amp\;A i
 ntegration\, diligence\, and deal sourcing.- Evaluating the roadmap for i
 ntegrating business development and the alliance management life-cycle.\n
DTEND:20210819T163000
DTSTAMP:20260512T231937Z
DTSTART:20210818T090000
LOCATION:Online\, \,
SEQUENCE:0
SUMMARY:COVID-19 has hit the pharmaceutical industry in the mergers and ac
 quisitions\, IP\, and due diligence areas within the life science industr
 y. The cha...
UID:0ff7297e-83d6-4463-929d-2001cd4fd816
END:VEVENT
END:VCALENDAR